Skip to main content

Advertisement

Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Suppressed diversity of survivin splicing in active rheumatoid arthritis

Fig. 4

Survivin splicing in blood and bone marrow leukocytes of RA patients treated with rituximab (RTX). a Disease Activity Score (DAS28) before and after RTX treatment. mRNA level of b survivin-WT and c survivin-2B in peripheral blood mononuclear cell (PBMC) and bone marrow (BM) leukocytes of 23 patients before and 1–3 months after RTX treatment. d Survivin-2B/WT ratio in BM before and 1–3 months after treatment. e Survivin-ΔEx3 in PBMCs and BM before and 1–3 months after RTX treatment. f Survivin-ΔEx3/WT ratio in BM before and after RTX treatment. Boxes represent the 25th–75th percentile of each group, horizontal lines indicate median value and error bars show the range. Comparison between groups performed with Mann–Whitney statistics. dCT difference in cycle threshold between survivin and glyceraldehyde 3-phosphate dehydrogenase, RQ relative quantity

Back to article page